AI Article Synopsis
- The guideline is aimed at clinicians in Japan for accurate diagnosis and prompt treatment of hereditary angioedema (HAE).
- It was created by the Japanese Association for Complement Research and was published in 2010.
- Updates to the guideline will be made as new medical advancements occur.
Article Abstract
This guideline was provided by the Japanese Association for Complement Research targeting clinicians for making an accurate diagnosis of hereditary angioedema (HAE), and for prompt treatment of the HAE patient in Japan. This is a 2010 year version and will be updated according to any pertinent medical advancements.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2332/allergolint.12-RAI-0471 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Anxiety to Work Productivity and Activity Impairment: The Mediating Role of Fatigue in Hereditary Angioedema.
Clin Exp Allergy
January 2025
Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong, SAR, China.
Specialty laboratory testing for chronic abdominal pain in irritable bowel syndrome.
Scand J Gastroenterol
January 2025
Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder seen by both primary care providers (PCPs) and gastroenterologists, and further diagnostic testing is generally discouraged unless red-flag symptoms are present.
Aims: Examine if advanced serologic testing for chronic abdominal pain in IBS patients followed society-specific guidelines and evaluate the diagnostic accuracy of these tests.
Methods: The study involved a retrospective cross-sectional analysis of adults aged 18 and older who were seen at our institution between 2013 and 2018.
Hereditary angioedema: patient healthcare experiences within underrepresented racial and ethnic groups in the United States.
Ann Allergy Asthma Immunol
January 2025
Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA.
Background: Hereditary angioedema (HAE) is a rare disorder in which unpredictable angioedema attacks significantly impact patient quality of life (QoL). There is limited information regarding patient experiences and perspectives of HAE management within underrepresented racial and ethnic groups.
Objective: To gain insight into the experiences and perspectives of medical care and treatment for HAE among underrepresented racial and ethnic groups in the US.
Identification of a novel mutation in the SERPING1 gene in a 17-year-old Chinese girl with type I hereditary angioedema.
JAAD Case Rep
February 2025
Department of Dermatology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, China.
Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.
J Comp Eff Res
February 2025
ICON plc, Insights, Evidence & Value - Health Economics & Epidemiology, Langen, Germany.
To compare the efficacy and safety of lanadelumab versus other approved long-term prophylaxis (LTP) treatments in patients with pediatric hereditary angioedema (HAE) aged <12 years. A systematic literature review was conducted to identify studies of LTP in patients with HAE aged <12 years. Two studies met the inclusion criteria in an indirect treatment comparison of efficacy and safety data in pediatric HAE patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!